Editorial


Nature Biotechnology 25, 363 (2007)
doi:10.1038/nbt0407-363

Sacrificing the cash cow


In view of concerns about safety, could Amgen's aggressive promotion of erythropoietin (EPO) have jeopardized its billion-dollar franchise?

Top



Extra navigation

Open Innovation Challenges

ADVERTISEMENT